Alebund Pharmaceuticals, R1 Therapeutics, AP306, EOS789, hyperphosphatemia, chronic kidney disease, CKD, hemodialysis, phosphate transporter inhibitor, Phase 2b clinical trial

Shanghai, China, and Denver, Colorado, USA, October 23, 2026 Alebund Pharmaceuticals and R1 Therapeutics have announced the presentation of...